Clinical Trials Study
Copyright ©The Author(s) 2025.
World J Gastrointest Pharmacol Ther. Jun 5, 2025; 16(2): 101268
Published online Jun 5, 2025. doi: 10.4292/wjgpt.v16.i2.101268
Table 1 Demographic and clinical features of the study population, n (%)/mean ± SD

Total sample (n = 61)
Active treatment (n = 40)
Placebo (n = 21)
P value
Age42 ± 1240 ± 1145 ± 130.12
Gender
Female43 (70.5)28 (70.0)15 (71.4)1.00
Male18 (29.5)12 (30.0)6 (28.6)
Diagnosis
CD44 (72.1)31 (77.5)13 (61.9)0.24
UC17 (27.9)9 (22.5)8 (38.1)
Disease duration13 ± 1010 ± 718 ± 12< 0.01
Previous resection16 (26.2)8 (20.0)8 (38.1)0.14
Biologic use40 (65.6)28 (70.0)12 (57.1)0.39
IBS severity
IBS-SSS at baseline285 ± 115272 ± 129308 ± 770.25
Mild9 (14.8)6 (15)3 (14)0.11 (severe vs mild-moderate)
Moderate26 (42.6)20 (50.0)6 (28.6)
Severe26 (42.6)14 (35.0)12 (57.1)
Table 2 Inflammatory bowel disease -related outcomes, n (%)

Total sample (n = 61)
Active agent (n = 40)
Placebo (n = 21)
P value
Biochemical flare8 (13.1)4 (10)4 (19.0)0.43
Steroid use or escalation of therapy8 (13.1)4 (10)4 (19.0)0.43
Biochemical flare or steroid or escalation of therapy10 (16.4)5 (12.5) 5 (23.8)0.29